Twist Bioscience
TWST
About: Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.
Employees: 923
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
44% more call options, than puts
Call options by funds: $3.47M | Put options by funds: $2.41M
2.15% more ownership
Funds ownership: 116.57% [Q1] → 118.72% (+2.15%) [Q2]
4% less capital invested
Capital invested by funds: $2.73B [Q1] → $2.62B (-$113M) [Q2]
9% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 88
8% less funds holding
Funds holding: 261 [Q1] → 241 (-20) [Q2]
33% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 52
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Financial journalist opinion
Based on 5 articles about TWST published over the past 30 days
